Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novo And Langer Lab Pursue Oral Peptides
by Lisa M. Jarvis
September 14, 2015
| A version of this story appeared in
Volume 93, Issue 36
Novo Nordisk will work with MIT professor Robert S. Langer to develop drug delivery devices for peptides. Working with Harvard biomedical engineer Giovanni Traverso, the team will look to deliver peptides, which are normally injected or administered intravenously, in a pill. The researchers must prevent the drug from degrading before it reaches its target, limit the variability of absorption, and find a cost-effective way to manufacture the product. Novo will fund research positions in Langer’s lab over the three years of the pact.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X